Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
Adv Anesth. 2024 Dec;42(1):1-26. doi: 10.1016/j.aan.2024.07.002. Epub 2024 Aug 28.
GlP-1 receptor agonists are a class of medications that are becoming increasingly popular. Large trials have shown that their use provides reliable weight loss in obese patients and improved glycemic control in diabetic patients. Its use also has broader implications for overall metabolic health and has been shown to improve cardiovascular outcomes in high-risk populations. Glucagon-like peptide 1 receptors cause multiple effects in the body through stimulation of receptors expressed in a broad range of tissues including the pancreas, liver, gastrointestinal tract, kidneys, heart, endothelium, muscle, and brain. For the anesthesia professionals the effects of these medications on gastric emptying is important.
GLP-1 受体激动剂是一类日益流行的药物。大型试验表明，它们的使用可在肥胖患者中可靠地减轻体重，并改善糖尿病患者的血糖控制。它的使用对整体代谢健康也具有更广泛的意义，并已显示可改善高危人群的心血管结局。胰高血糖素样肽 1 受体通过刺激在广泛的组织（包括胰腺、肝脏、胃肠道、肾脏、心脏、内皮细胞、肌肉和大脑）中表达的受体，在体内引起多种作用。对于麻醉专业人员来说，这些药物对胃排空的影响很重要。
